Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Clinical trial NCT07633626 · RECRUITING

Trial details

NCT number: NCT07633626
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Status: RECRUITING
Study type: OBSERVATIONAL

Advanced ALK/ROS1-positive NSCLC Carcinoma, Non-Small-Cell Lung (NSCLC)Lung Adenocarcinoma ALK-positive Non-small Cell Lung Cancer (NSCLC)Cognitive Dysfunction Depression

Start date: 2026-03-10
Primary completion: 2027-03-10
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.